Sanofi-Aventis Europe, a division of the French drug major, has opened an offer to acquire all issued ordinary shares, including those held in the form of GDSs, of Czech generics company Zentiva for 40.04 billion koruna ($2.67 billion).
This equates to 1,050 koruna per share, a 14.6 % premium over the April 30 closing price of 916.60 koruna. The previous announcement of the bid (Marketletter June 23) eclipsed an offer of 950 koruna per share by Dutch conglomerate PPF through its subsidiary Anthiarose.
Offer open to September 19
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze